Novel curcumin analogs act as antagonists to control nosocomial infection causing Pseudomonas aeruginosa. (July 2019)

• Record Type: Journal Article
• Authors: Shanmugasundaram, P.; Saroj Kumar, Sah; Ubaid, Rasool; Mahasampath Gowri, S.; Easwaramoorthy, D.; Hemalatha, S.
• Is Part Of: Biocatalysis and agricultural biotechnology. Number 20(2019)
• Publication Date: 2019-07
• Subjects: Curcumin analogs -- Piperidinylthiazole derivatives -- Pseudomonas aeruginosa -- Antibacterial; Agricultural biotechnology -- Periodicals; Enzymes -- Biotechnology -- Periodicals; 660.6
• DOI: 10.1016/j.bcab.2019.101238
• Languages: English
• ISSNs: 1878-8181

Abstract

Abstract: Pseudomonas aeruginosa has become the important cause of hospital acquired nosocomial infection which is one of the leading cause of death in today's world. Here, we synthesized structurally similar analogs of curcumin (G0-G4) as antagonist to the growth and virulence of P. aeruginosa. The structural skeleton of analogs comprises of central bridging ligands of cyclic ketones which are flanked by side chain made up of N-Boc protected piperidinylthiazole moiety. The rationale of selecting piperidinylthiazole based pharmacophore is attributed to its therapeutic potential and aromaticity similar to curcumin. Based on the structure-activity comparison, the growth inhibitory properties of test compounds are mainly driven by side-chain pharmacophore of N-Boc protected piperidinylthiazole moiety which could be used as lead for further studies. Graphical abstract: Image 1 Highlights: Five Novel curcumin analogs were synthesized from Piperidinylthiazole derivatives. Structurally similar to curcumin skeleton. Novel curcumin analogs as antagonists to control infection causing P.aeruginosa . These can be utilized as lead compounds for clinical applications.